Angiogenesis is critical for tumor nutrient access and progression, rendering it an attractive therapeutic target. To date, antiangiogenic therapies have lacked success due to side effects and therapeutic resistance. Therefore, antiangiogenic therapy may be enhanced using novel molecular targets that regulate angiogenesis and other oncogenic processes. In their study on page 77, Kumar and colleagues demonstrate that in addition to previously established roles in epithelial–mesenchymal transition and poor patient outcomes, IQGAP2 suppression induces breast tumor angiogenesis. The cover depicts an ImageJ Angiogenesis Analyzer image of human umbilical vein endothelial cell tubules in culture with conditioned medium from breast cancer cells in which IQGAP2 expression has been reduced using shRNA. This article is also Highlighted on page 1.